ClinicalTrials.gg
CompletedNCT03505021REFALSUpdated May 11, 2022Results posted

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

A Phase 3 interventional study of Levosimendan and Placebo for levosimendan in Amyotrophic Lateral Sclerosis, sponsored by Orion Corporation, Orion Pharma. Completed at 104 sites in 14 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Orion Corporation, Orion Pharma · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
15th of 307
496 · median 33
Started
2018
with 19 others
Phase 3
30 of 440
3 open now
Registered
214th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 15th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2018, is one of 30 in phase 3, and was the 214th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale. In this randomized, double-blind, placebo-controlled, parallel-group, multicenter study, subjects are allocated in a 2:1 ratio to receive either levosimendan (1 -2 mg daily) or placebo for 48 weeks. The primary endpoint is slow vital capacity (SVC) at 12 weeks, with the impact on patient function assessed through 48 weeks, adjusted for patient outcome, using ALSFRS-R (combined assessment of function and survival, CAFS). Other important efficacy measures include time to respiratory events, clinical global impression (CGI), assessment of dyspnea using the Borg scale and sleep scales (Pittsburgh sleep quality index and Epworth sleepiness scale). Patient safety is monitored using conventional methods including adverse events, safety laboratory tests, vital signs and 12-lead EKG. Following screening and baseline visits, patients attend the clinic at 2, 4, 8, 12, 24, 36 and 48 weeks, with telephone assessments conducted at weeks 18, 30 and 42. An end of study visit is performed 14-25 days after the last study treatment administration. The study will be monitored by an independent data and safety monitoring board. A long-term extension study will be available for patients completing the study.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written or verbal (IC) for participation in the study
  • Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria. Full electromyogram (EMG) report available consistent with ALS (but not necessarily fulfilling the electrodiagnostic criteria for ALS) from an experienced neurophysiologist
  • Able to swallow study treatment capsules, and in the opinion of the investigator, is expected to continue to do so during the study
  • Sitting SVC between 60-90% of the predicted value for age, height and sex at screening visit
  • Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12-48 months at the time of visit 1 (baseline)
  • Able to perform supine SVC in an adequate and reliable way at screening and baseline visits as judged by the investigator
  • Subjects with or without riluzole and/or edaravone. If using riluzole (any daily dose up to 100 mg), the dose must have been stable for at least 4 weeks before the screening visit and should not be changed during the study. If using edaravone, the treatment should have been started at least 4 weeks before the screening visit (at least one 28-day treatment cycle as indicated) and should not be changed during the study. If not on riluzole and/or edaravone, the respective treatments should not be started during the study

Exclusion criteria

Exclusion Criteria:

  • Subject in whom other causes of neuromuscular weakness have not been excluded
  • Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson's or Alzheimer's disease)
  • Assisted ventilation of any type within 3 months before the screening visit or at screening
  • Any use of a diaphragm pacing system (DPS) within 3 months before the screening visit
  • Any form of stem cell or gene therapy for the treatment of ALS
  • Known to levosimendan
  • Administration of levosimendan within 3 months before the screening visit or previous participation in the present phase III study or earlier study with oral levosimendan in ALS patients (LEVALS)
  • Any use of tirasemtiv or reldesemtiv within 1 month before the screening visit.
  • Participation in a clinical trial with any experimental treatment within 30 days or within 5 half-lives of that treatment (whichever is longer) before the screening visit
  • Any botulinum toxin use within 3 months before the screening visit
  • Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia that may interfere with the patient's ability to comply with study procedures
  • Pulmonary illness (e.g. asthma or ) requiring regular treatment
  • Haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy
  • Any cardiovascular event (e.g. myocardial infarction, HF, arrhythmia or stroke) requiring hospitalisation within 3 months before the screening visit
  • History of Torsades de Pointes (TdP) or diagnosed long -syndrome
  • History of life-threatening ventricular arrhythmia, unless treated with reliable measures to prevent recurrence (e.g. with placement of implantable cardioverter defibrillator [ICD] or catheter ablation)
  • History of second or third degree atrioventricular (AV) block or sinus node disease at screening, if not treated with pacemaker
  • HR repeatedly > 100 bpm in the 12-lead after a 5-minute rest at screening. If the HR is > 100 bpm in the first recording, then the second recording must be done after another 5 min rest to confirm HR > 100 bpm
  • Systolic blood pressure (SBP) \< 90 mmHg at screening
  • Potassium \< 3.7 mmol/l or > 5.5 mmol/l at screening
  • Severe renal impairment ( \< 30 ml/min at screening), creatinine > 170 μmol/l at screening or on dialysis
  • Blood \< 10 g/dl at screening or blood donation or loss of significant amount of blood within 60 days before the screening visit
  • hepatic impairment at the discretion of the investigator
  • (BMI) ≤ 18.5kg/m2 (BMI = weight/height2)
  • Women who are lactating or of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of (e.g. oral hormonal contraceptives associated with inhibition of ovulation, intrauterine devices and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included
  • Patient judged to be actively suicidal by the investigator during 3 months before the screening visit
  • Patients with known history of (HIV) infection
  • Any other clinically significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
496 participants (actual)

Study arms

  • Experimental
    Levosimendan

    Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks

    Drug: Levosimendan

  • Placebo comparator
    Placebo for levosimendan

    Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.

    Drug: Placebo for levosimendan

Interventions

  • DrugSimendanStudies of SimendanSimendan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Levosimendan 1 mg capsule for oral administration

    Also known as: ODM-109

  • DrugPlacebo for levosimendan

    Placebo capsule for oral administration

    Also known as: Placebo for ODM-109

06

What researchers measure

Primary outcomes

  1. Supine Slow Vital Capacity (SVC)

    Change from baseline to 12 weeks, expressed as % of predicted normal.

    Time frame: The change from baseline at 12 weeks

Secondary outcomes

  1. Combined Assessment of Function and Survival Through 48 Weeks

    Scale: The ALS Functional Rating Scale - Revised. This scale includes 12 items. Each item was scored from 0 to 4. Total score is the sum of the scores of all 12 items. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than after deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 496 (the number of participants assessed for the Outcome Measure) with larger rank score numbers associated with a better outcome.

    Time frame: Mean rank at 48 weeks

  2. Time to Respiratory Event Through 48 Weeks

    ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. A reduction in any one of these items was considered a respiratory event. Not all patients receive ventilatory support, despite respiratory insufficiency: meeting "protocolised" criteria for NIV relates to patients without NIV whose slow vital capacity declined to a level that would ordinarily trigger such treatment.

    Time frame: Time to event through 48 weeks

  3. Change From the Baseline in Clinical Global Impression CGI at 48 Weeks

    Visual Analogue Scale 0-100 millimeters, rated by study subjects. Score 0 indicates that the subject is completely well without any disability and score 100 indicates the worst possible severity of the condition.

    Time frame: The change from baseline at 48 weeks

  4. Change From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks

    ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. These are added together to created the respiratory domain with a score range 0-12 (where 12 represents normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected to reduce the slope of decline.

    Time frame: Slope of decline at 48 weeks

  5. Supine Borg Category Ratio 10 Scale at 12 Weeks

    Patients rated their perception of the severity of their dysnoea using the Borg scale. The scale ranges from 0 (no dyspnoea) to 10 (maximal). Each category is numbered and most (not all) have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline at 12 weeks, where a negative score indicates improvement and a positive score reflects worsening.

    Time frame: Change from baseline at 12 weeks

07

Results

Posted Aug 31, 2021

Participant flow

Patients with amyotrophic lateral sclerosis (ALS) were recruited.

Participant flow — Overall Study
MilestoneLevosimendanPlacebo for Levosimendan
Started329167
Completed217112
Not completed11255
Withdrew: Protocol violation10
Withdrew: Death98
Withdrew: Consent withdrawn by subject61
Withdrew: Lost to follow-up53
Withdrew: Adverse event269
Withdrew: Disease progression3317
Withdrew: Other115
Withdrew: Personal reason2112

Outcome measures

PrimarySupine Slow Vital Capacity (SVC)

Change from baseline to 12 weeks, expressed as % of predicted normal.

Time frame:
The change from baseline at 12 weeks
Reported as:
Least squares mean · percentage
Supine Slow Vital Capacity (SVC)
percentageLevosimendanPlacebo for Levosimendan
Supine Slow Vital Capacity (SVC)-6.731 (-8.290 to -5.171)-6.988 (-9.052 to -4.925)
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · ANCOVA · p = 0.8253 · Mean difference (final values): 0.258 · 95% CI -2.032 to 2.547
SecondaryCombined Assessment of Function and Survival Through 48 Weeks

Scale: The ALS Functional Rating Scale - Revised. This scale includes 12 items. Each item was scored from 0 to 4. Total score is the sum of the scores of all 12 items. Each subject is ranked according to time-to-death (earlier deaths ranked lower than later deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than after deaths). Subjects who survive are ranked more favorably than subjects who died. Among the survivors, subjects are ranked according to change in ALSFRS-R (greater worsening of ALSFRS-R is ranked lower than less worsening or an improvement in ALSFRS-R). The ranked scores range from 001 to 496 (the number of participants assessed for the Outcome Measure) with larger rank score numbers associated with a better outcome.

Time frame:
Mean rank at 48 weeks
Reported as:
Least squares mean · Scores on a rank scale
Combined Assessment of Function and Survival Through 48 Weeks
Scores on a rank scaleLevosimendanPlacebo for Levosimendan
Combined Assessment of Function and Survival Through 48 Weeks239.85 ± 10.98229.16 ± 13.31
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · ANCOVA · p = 0.4277 · Mean difference (final values): 10.69 · 95% CI -15.74 to 37.12
SecondaryTime to Respiratory Event Through 48 Weeks

ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. A reduction in any one of these items was considered a respiratory event. Not all patients receive ventilatory support, despite respiratory insufficiency: meeting "protocolised" criteria for NIV relates to patients without NIV whose slow vital capacity declined to a level that would ordinarily trigger such treatment.

Time frame:
Time to event through 48 weeks
Reported as:
Median · Days
Time to Respiratory Event Through 48 Weeks
DaysLevosimendanPlacebo for Levosimendan
Time to Respiratory Event Through 48 Weeks90 (82 to 144)126 (82 to 169)
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · Regression, Cox · p = 0.6733 · Hazard ratio (hr): 1.051 · 95% CI 0.833 to 1.327
SecondaryChange From the Baseline in Clinical Global Impression CGI at 48 Weeks

Visual Analogue Scale 0-100 millimeters, rated by study subjects. Score 0 indicates that the subject is completely well without any disability and score 100 indicates the worst possible severity of the condition.

Time frame:
The change from baseline at 48 weeks
Reported as:
Least squares mean · units on a scale
Change From the Baseline in Clinical Global Impression CGI at 48 Weeks
units on a scaleLevosimendanPlacebo for Levosimendan
Change From the Baseline in Clinical Global Impression CGI at 48 Weeks17.048 (14.111 to 19.984)13.285 (9.252 to 17.318)
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · ANCOVA · p = 0.1295 · Mean difference (final values): 3.762 · 95% CI -1.129 to 8.654
SecondaryChange From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks

ALSFRS-R scale contains 3 items that relate to respiratory function: severity of dyspnoea, occurrence of orthopnoea (shortness of breath when lying flat) and the use of mechanical ventilation for respiratory insufficiency. These are added together to created the respiratory domain with a score range 0-12 (where 12 represents normal function). Although individual items and patients vary, ALSFRS-R typically declines at a relatively constant rate over time. Plotted over time the slope of the line obtained indicates the speed of progression and thus an effective treatment might be expected to reduce the slope of decline.

Time frame:
Slope of decline at 48 weeks
Reported as:
Least squares mean · Score on a scale/month
Change From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks
Score on a scale/monthLevosimendanPlacebo for Levosimendan
Change From Baseline in Respiratory Function of ALSFRS-R at 48 Weeks-0.191 ± 0.015-0.205 ± 0.022
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · Mixed Models Analysis · p = 0.6230 · Mean difference (final values): 0.013 · 95% CI -0.040 to 0.066
SecondarySupine Borg Category Ratio 10 Scale at 12 Weeks

Patients rated their perception of the severity of their dysnoea using the Borg scale. The scale ranges from 0 (no dyspnoea) to 10 (maximal). Each category is numbered and most (not all) have verbal cues. At each assessment the patient scored the category they felt best described their symptoms. The analysis measured change from baseline at 12 weeks, where a negative score indicates improvement and a positive score reflects worsening.

Time frame:
Change from baseline at 12 weeks
Reported as:
Least squares mean · score on a scale
Supine Borg Category Ratio 10 Scale at 12 Weeks
score on a scaleLevosimendanPlacebo for Levosimendan
Supine Borg Category Ratio 10 Scale at 12 Weeks-0.152 ± 0.1380.120 ± 0.186
Statistical analysis
  • Levosimendan vs Placebo for Levosimendan · ANCOVA · p = 0.1752 · Mean difference (final values): -0.272 · 95% CI -0.666 to 0.122

Adverse events

Collected over From signing an informed consent until 25 days from stopping the treatment, up to 51 weeks.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levosimendan27/326 (8.3%)89/326 (27.3%)312/326 (95.7%)
Placebo for Levosimendan17/166 (10.2%)45/166 (27.1%)157/166 (94.6%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventLevosimendanPlacebo for Levosimendan
PneumoniaInfections and infestations12/3267/166
FallInjury, poisoning and procedural complications13/3266/166
Respiratory failureRespiratory, thoracic and mediastinal disorders13/3265/166
Urinary tract infectionInfections and infestations1/3265/166
Pulmonary embolismRespiratory, thoracic and mediastinal disorders9/3264/166
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders8/3262/166
DyspnoeaRespiratory, thoracic and mediastinal disorders7/3263/166
Amyotrophic lateral sclerosisNervous system disorders4/3263/166
Chest painGeneral disorders4/3261/166
Confusional statePsychiatric disorders1/3262/166
Most frequent other events
Showing 10 of 36
Most frequent other events
EventLevosimendanPlacebo for Levosimendan
HeadacheNervous system disorders101/32636/166
FallInjury, poisoning and procedural complications86/32645/166
Heart rate increasedInvestigations64/3265/166
DyspnoeaRespiratory, thoracic and mediastinal disorders54/32630/166
DysphagiaGastrointestinal disorders47/32627/166
NasopharyngitisInfections and infestations52/32626/166
ConstipationGastrointestinal disorders38/32621/166
Muscular weaknessMusculoskeletal and connective tissue disorders31/32618/166
Urinary tract infectionInfections and infestations25/32617/166
TachycardiaCardiac disorders32/3268/166

Baseline characteristics

Intention-to-treat (ITT) dataset, including all randomised subjects, was used for the primary evaluation. Sensitivity analyses using full analysis set (FAS) and two per-protocol (PP) datasets (up to 12 weeks and up to 48 weeks) were performed. FAS included all treated subjects with at least one post baseline SVC measurement. PP dataset included all randomised subjects except subjects with relevant major protocol deviations.

Age, Continuous
Age, Continuous(years)LevosimendanPlacebo for LevosimendanTotal
Mean59 ± 11.259.7 ± 10.859.3 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)LevosimendanPlacebo for LevosimendanTotal
Female12267189
Male207100307
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LevosimendanPlacebo for LevosimendanTotal
American Indian or Alaska Native000
Asian9110
Native Hawaiian or Other Pacific Islander000
Black or African American538
White305157462
More than one race101
Unknown or Not Reported9615
Region of Enrollment
Region of Enrollment(participants)LevosimendanPlacebo for LevosimendanTotal
United States10545150
United Kingdom819
Spain441559
Canada252247
Austria617
Netherlands8816
Sweden19726
Belgium121022
Ireland325
Finland10313
Italy181634
Australia14620
France358
Germany542680
08

Study locations

104 sites
  • Phoenix Neurological Associates
    Phoenix, Arizona 85006, United States
  • Neuromuscular Research Center and Neuromuscular Clinic of Arizona
    Phoenix, Arizona 85028, United States
  • University of California San Diego
    La Jolla, California 92037-0886, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Irvine
    Orange, California 92868, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • Hospital for Special Care
    New Britain, Connecticut 06053, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion
    Washington, District of Columbia 20037, United States
  • Providence Holy Cross Medical Center
    Fort Lauderdale, Florida 33308, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Florida Health - Jacksonville
    Jacksonville, Florida 32209, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • Kentucky Neuroscience Research
    Louisville, Kentucky 40202, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 49007, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • HealthPartners Specialty Center
    Saint Paul, Minnesota 55130-5302, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Neurology Associates
    Lincoln, Nebraska 68506, United States
  • Mount Sinai Beth Israel
    New York, New York 10003, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Columbia Presbyterian Hospital
    New York, New York 10032, United States
  • Neurosciences Institute - Neurology Charlotte
    Charlotte, North Carolina 28207, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157-1023, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University
    Portland, Oregon 97201-3098, United States
  • Providence Brain and Spine Institute
    Portland, Oregon 97213, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Texas Neurology
    Dallas, Texas 75214, United States
  • Nerve and Muscle Center of Texas
    Houston, Texas 77030, United States
  • University of Utah - Imaging & Neurosciences Center
    Salt Lake City, Utah 84108, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Brain and Mind Centre
    Camperdown, New South Wales 2050, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Calvary Health Care Bethlehem
    Caulfield South, Victoria 3162, Australia
  • Perron Institute for Neurological and Translational Science
    Murdoch, Western Australia 6150, Australia
  • Universität Innsbruck
    Innsbruck, Tyrol 6020, Austria
  • Salzkammergut-Klinikum Vöcklabruck
    Vöcklabruck, Upper Austria 4840, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Universitaire Ziekenhuis Leuven
    Leuven, Flemish Brabant 3000, Belgium
  • Centre Hospitalier Régional de la Citadelle
    Liège, Liege 4000, Belgium
  • Algemeen Ziekenhuis St. Lucas Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • Alberta Health Services - Neuromuscular Clinic
    Calgary, Alberta T3M 1M4, Canada
  • University of Alberta
    Edmonton, Alberta T6G 2G3, Canada
  • Stan Cassidy Centre for Rehabilitation
    Fredericton, New Brunswick E3B 0C7, Canada
  • Moncton Hospital, Southeast Regional Health Authority
    Moncton, New Brunswick E1C 2Z3, Canada
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Centre De Recherche Du Centre Hospitalier de l'Universite de Montreal - Hopital Notre-Dame
    Montréal, Quebec H2L 4M1, Canada
  • Montreal Neurological Institute and Hospital
    Montréal, Quebec H3A 2B4, Canada
  • Centre Hospitalier Affilie Universitaire de Quebec
    Québec, Quebec G1J 1Z4, Canada
  • Neurologian Poliklinikka - Meilahden Tornisairaala 3
    Helsinki, 00029, Finland
  • Etelä-Karjalan keskussairaala
    Lappeenranta, 53130, Finland
  • Turku University Hospital
    Turku, 20521, Finland
  • Centre Hospitalier Universitaire de Limoges
    Limoges, 87042, France
  • Hôpital Gui de Chauliac
    Montpellier, 34295, France
  • Hôpital Pasteur
    Nice, 06202, France
  • Centre Hospitalier Régional et Universitaire de Tours Hôpital Bretonneau
    Tours, 37044, France
  • Universitätsklinikum Ulm
    Ulm, Baden-Württemberg 89081, Germany
  • Deutsche Klinik für Diagnostik
    Wiesbaden, Hessen 65191, Germany
  • Universitätsmedizin Rostock
    Rostock, Mecklenburg-western-pommerania 18147, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Alfried Krupp Krankenhaus Rüttenscheid
    Essen, Nordrhein-westfalen 45131, Germany
  • Universitätsklinikum Münster
    Münster, Nordrhein-Westfalen 48149, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen 01307, Germany
  • Universitätsklinikum Jena
    Jena, Thuringen 07747, Germany
  • Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Beaumont Hospital - Ireland
    Dublin, 9, Ireland
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Azienda Ospedaliera Universitaria-Maggiore della Carità di Novara
    Novara, 28100, Italy
  • ICS Maugeri Spa SB
    Pavia, 27100, Italy
  • Azienda Ospedaliero-Universitaria Pisana Ospedale Santa Chiara
    Pisa, 56126, Italy
  • Policlinico Umberto I di Roma
    Roma, 0016, Italy
  • Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Academisch Medisch Centrum
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Universitair Medisch Centrum Utrecht - Rudolf Magnus Instituut voor Neurowetenschappen
    Utrecht, 3584 CG, Netherlands
  • Hospital de Basurto
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08207, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14011, Spain
  • Hospital San Rafael - Madrid
    Madrid, 28016, Spain
  • Hospital Universitario y Politécnico de La Fe
    Valencia, 46026, Spain
  • Norrlands Universitetssjukhus
    Umeå, Vasterbotten 90737, Sweden
  • Centralsjukhuset Karlstad
    Karlstad, 651 85, Sweden

Showing the first 100 of 104 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamaki M, Garratt C, Al-Chalabi A; REFALS investigators. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. PubMed 34536404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jul 2020, 25 months.

Results were first posted in Aug 2021, 1 year 1 month after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2018
First posted
Apr 20, 2018
StartActual
Jun 21, 2018
Primary completionActual
Jul 23, 2020
CompletionActual
Jul 23, 2020
Results first posted
Aug 31, 2021
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03505021
Responsible party
Sponsor
First posted
Apr 20, 2018
Start date
Jun 21, 2018
Primary completion
Jul 23, 2020
Completion
Jul 23, 2020
Results posted
Aug 31, 2021
Last update
May 11, 2022

Study contacts

Merja Mäkitalo, CSD
study director · Orion Corporation, Orion Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion